OVERVIEW

Important Update from the Course Directors:
The in-person Child & Adolescent Psychopharmacology 2020 course has been switched due to a precautionary Coronavirus mandate from the Health Department. We are now going to live-stream the course over the internet on the same dates and times.

Child & Adolescent Psychopharmacology 2020 is organized by Massachusetts General Hospital (MGH) and will be held from Mar 20 - 22, 2020.

Accreditation:
• 22.5 AMA PRA Category 1 Credit(s)™.
• 22.5 Psychologists CE Credit.
• 22.5 Nursing Contact Hours.
• 22.5 Social Workers.
• 22.5 Other Professions.

Target Audience:
This program is intended for:
• Psychiatrists
• Primary care and family practice physicians
• Pediatricians
• Psychologists
• Nursing professionals
• Social workers
• Residents
• Other mental health, primary care and pediatric clinicians

Course Description:
This renowned conference provides a complete update across research, assessment, and treatment of mental health conditions in children and adolescents. It is ideal if you work in mental health, primary care, nursing, psychology, school health, and more.

• Hear guidance on translating new research into clinical practice for substance use disorders, mood disorders, OCD, schizophrenia, anxiety disorders, and more
• Find sessions on pharmacologic treatments, psychological interventions, naturopathic treatments, suicide risk and prevention, implications of genetics, and much more
• Ask questions and discuss cases during Curbside Consultation hours with experts on specific topics
• Find insights that enhance your clinical work in psychiatric practices, community clinics, hospitals, school-based settings, primary care offices, university clinics, and psychology practices

Learning Objectives:
At the end of this educational activity, participants should be able to:
• Recognize the presentation, diagnosis, and current treatmentoptions available for attention deficit and hyperactivity in childhood and adolescence.
• Identify the presentation, diagnosis, and current treatment options available for behavioral problems and pervasive developmental disorders.
• Discuss the presentation, diagnosis, and current treatment options available for depression, psychosis, manic depression, and anxiety.
• Compare and contrast basic neuropharmacology, neuropsychologic testing data, psychopharmacologic properties of compounds, and the implications of psychiatric genetics for guiding day-to-day pediatric psychopharmacology treatment.
• Recognize the risk management issues associated with adolescent substance use disorder and smoking, ethical and safe use of psychotropics, suicide risk and prevention, cardiovascular side effects and medical liability of stimulants, and liability prevention in psychopharmacology.
• Review the comorbidiy of ADHD with posttraumatic stress disorder and traumatic brain injury.
• Explore emotional dysregulation, executive function and learning disorders in the context of ADHD.